Volume : 09, Issue : 06, June – 2022



Authors :

Dr.Goday Swapna *, Joy Shalom

Abstract :

The aim of present investigation was to formulate and evaluate floating tablet of telmisartan. Artificial Intelligence (AI) focuses in producing intelligent modelling, which helps in imagining knowledge, cracking problems and decision making. Recently, AI plays an important role in various fields of pharmacy like drug discovery, drug delivery formulation development, polypharmacology, hospital pharmacy, etc. In drug discovery and drug delivery formulation development, various Artificial Neural Networks (ANNs) like Deep Neural Networks (DNNs) or Recurrent Neural Networks (RNNs) are being employed. Several implementations of drug discovery have currently been analysed and supported the power of the technology in quantitative structure-property relationship (QSPR) or quantitative structure-activity relationship (QSAR). In addition, de novo design promotes the invention of significantly newer drug molecules with regard to desired/optimal qualities. In the current review article, the uses of AI in pharmacy, especially in drug discovery, drug delivery formulation development, polypharmacology and hospital pharmacy are discussed.
Key words: Artificial intelligence, Artificial neural network, Drug discovery, Drug delivery research

Cite This Article:

Please cite this article in press Goday Swapna et al, Artificial Intelligence In Pharmaceutical Industry: A Review., Indo Am. J. P. Sci, 2022; 09(6).,

Number of Downloads : 10


1. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24(3):773-80.
2. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019;151:169-90.
3. Russel S, Dewey D, Tegmark M. Research priorities for robust and beneficial artificial intelligence. AI Mag. 2015;36(4):105-14.
4. Duch W, Setiono R, Zurada JM. Computational intelligence methods for rulebased data understanding. Proc IEEE. 2004;92(5):771-805.
5. Dasta JF. Application of artificial intelligence to pharmacy and medicine. Hosp Pharm. 1992;27(4):319-22.
6. Jiang F, Jiang Y, Zhi H. Artificial intelligence in healthcare: Past, present and future. Stroke Vasc Neurol. 2017;2(4):230-43.
7. Gobburu JV, Chen EP. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. J Pharm Sci. 1996;85(5):505-10.
8. Sakiyama Y. The use of machine learning and nonlinear statistical tools for ADME prediction. Expert Opin Drug Metab Toxicol. 2009;5(2):149-69.
9. Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J Pharm Biomed Anal. 2000;22(5):717-27.
10. Zhang ZH, Wang Y, Wu WF, Zhao X, Sun XC, Wang HQ. Development of glipizide push-pull osmotic pump controlled release tablets by using expert system and artificial neural network. Yao Xue Xue Bao. 2012;47(12):1687-95.
11. Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. Deep neural nets as a method for quantitative structure–activity relationships. J Chem Inf Model. 2015;55(2):263-74.
12. Mayr A, Klambauer G, Unterthiner T, Hochreither S. Deep Tox: Toxicity prediction using Deep Learning. Front Environ Sci. 2016;3:80.
13. Bishop CM. Model-based machine learning. Philos Trans A Math Phys Eng Sci. 2013;371(1984):20120222.
14. Merk D, Friedrich L, Grisoni F, Schneider G. De novo design of bioactive small molecules by artificial intelligence. Mol Inform. 2018;37(1-2):1-4.
15. Manikiran SS, Prasanthi NL. Artificial Intelligence: Milestones and Role in Pharma and Healthcare Sector. Pharma Times. 2019;51(1):10-1.
16. Cherkasov A, Hilpert K, Jenssen H, Fjell CD, Waldbrook M, Mullaly SC, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic resistant superbugs. ACS Chem Biol. 2009;4(1):65-74.
17. Haykin S. Neural Networks: A Comprehensive Foundation, 1st ed. PrenticeHall PTR. NJ, United State. 1998.
18. Zupan J, Gasteiger J. Neural nets for mass and vibrational spectra. J Mol Struct. 1993;292:141-59.
19. Achanta AS, Kowalski JG, Rhodes CT. Artificial neural networks: Implications for pharmaceutical sciences. Drug Dev Ind Pharm. 1995;21(1):119-55.
20. Sakiyama Y. The use of machine learning and nonlinear statistical tools for ADME prediction. Expert Opin Drug Metab Toxicol. 2009;5(2):149-69.
21. Sutariya V, Groshev A, Sadana P, Bhatia D, Pathak Y. Artificial neural network in drug delivery and pharmaceutical research. Open Bioinf J. 2013;7(1):49-62.
22. Gutiérrez PA, Hervás-Martínez C. Hybrid Artificial Neural Networks: Models, Algorithms and Data. Advances in Computational Intelligence, Lecture Notes in Computer Science, Springer, Berlin, Heidelberg. 2011;6692.
23. Taskinen J, Yliruusi J. Prediction of physicochemical properties based on neural network modeling. Adv Drug Deliv Rev. 2003;55(9):1163-83.
24. Fleming N. How artificial intelligence is changing drug discovery. Nature. 2018;557(7706):S55-7. 25. Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev. 2003;55(9):1201-15.
26. Zadeh LA. Fuzzy sets. Inform Control. 1965;8:338-53.
27. Huang JW, Roy RJ. Multiple-drug hemodynamic control using fuzzy decision theory. IEEE Transact Biomed Eng. 1998;45(2):213-28.
28. Held CM, Roy RJ. Multiple drug hemodynamic control by means of a supervisory fuzzy rule-based adaptive control system: Validation on a model. IEEE Trans Biomed Eng. 1995;42(4):371-85. 29. Fatouros DG, Nielsen FS, Douroumis D, Hadjileontiadis LJ, Mullertz A. In vitro–in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Eur J Pharm Biopharm. 2008;699(3):887-98.
30. Jolliffe IT, Jorge C. Principal component analysis: A review and recent developments. Phil Trans R Soc A. 2016;374(2065):20150202.
31. Jolliffe IT Principal Component Analysis” Springer-Verlag, (New York). 2002.
32. Giuliani A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov Today. 2017;22(7):1069-76.
33. Silver D, Schrittwieser J, Simonyan K. Mastering the game of Go without human knowledge. Nature. 2017;550(7676):354-9